BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience
BioAdaptives (OTC:BDPTD) announced the national launch of NeuroRush™, a next-generation nootropic supplement, scheduled for commercial release in August/September 2025. The product combines six clinically studied ingredients including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens.
The supplement will be available in two formulations: one with natural caffeine and a caffeine-free version. Following successful test market results, the company plans to distribute NeuroRush™ through online retailers, direct-to-consumer channels, and health & wellness partners nationwide.
BioAdaptives (OTC:BDPTD) ha annunciato il lancio nazionale di NeuroRush™, un integratore nootropico di nuova generazione, previsto per il rilascio commerciale ad agosto/settembre 2025. Il prodotto combina sei ingredienti clinicamente studiati tra cui Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng e Mucuna Pruriens.
L'integratore sarà disponibile in due formulazioni: una con caffeina naturale e una senza caffeina. Dopo i risultati positivi del test di mercato, l'azienda prevede di distribuire NeuroRush™ tramite rivenditori online, canali diretti al consumatore e partner nel settore della salute e del benessere a livello nazionale.
BioAdaptives (OTC:BDPTD) anunció el lanzamiento nacional de NeuroRush™, un suplemento nootrópico de próxima generación, programado para su comercialización en agosto/septiembre de 2025. El producto combina seis ingredientes clínicamente estudiados incluyendo Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng y Mucuna Pruriens.
El suplemento estará disponible en dos formulaciones: una con cafeína natural y otra sin cafeína. Tras los exitosos resultados en el mercado de prueba, la compañía planea distribuir NeuroRush™ a través de minoristas en línea, canales directos al consumidor y socios de salud y bienestar a nivel nacional.
BioAdaptives (OTC:BDPTD)는 차세대 뇌기능 개선 보조제인 NeuroRush™의 전국 출시를 2025년 8월/9월에 상업적으로 진행할 예정이라고 발표했습니다. 이 제품은 Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, Mucuna Pruriens 등 임상적으로 연구된 6가지 성분을 결합했습니다.
이 보조제는 두 가지 제형으로 제공됩니다: 천연 카페인이 포함된 제품과 무카페인 제품. 성공적인 시험 시장 결과 이후, 회사는 NeuroRush™를 온라인 소매업체, 직접 소비자 채널 및 전국 건강 및 웰니스 파트너를 통해 유통할 계획입니다.
BioAdaptives (OTC:BDPTD) a annoncé le lancement national de NeuroRush™, un supplément nootropique de nouvelle génération, prévu pour une commercialisation en août/septembre 2025. Le produit combine six ingrédients cliniquement étudiés incluant Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng et Mucuna Pruriens.
Le supplément sera disponible en deux formulations : une avec caféine naturelle et une version sans caféine. Suite aux résultats positifs des tests de marché, la société prévoit de distribuer NeuroRush™ via des détaillants en ligne, des canaux directs aux consommateurs et des partenaires santé et bien-être à l’échelle nationale.
BioAdaptives (OTC:BDPTD) kündigte die landesweite Markteinführung von NeuroRush™ an, einem Nootropikum der nächsten Generation, das für August/September 2025 geplant ist. Das Produkt kombiniert sechs klinisch untersuchte Inhaltsstoffe, darunter Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng und Mucuna Pruriens.
Das Supplement wird in zwei Formulierungen erhältlich sein: eine mit natürlichem Koffein und eine koffeinfreie Variante. Nach erfolgreichen Testmarkt-Ergebnissen plant das Unternehmen, NeuroRush™ über Online-Händler, Direktvertrieb und Partner im Gesundheits- und Wellnessbereich landesweit zu vertreiben.
- Strong results reported in targeted test market trials
- Product offers two formulations to address different consumer needs
- Multiple distribution channels planned for nationwide reach
- None.
NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout.
LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) -- BioAdaptives, Inc. (OTC: BDPT), an innovator in evidence-based wellness solutions, today announced the upcoming national release of NeuroRush™, a next-generation nootropic designed to support sustained cognitive performance, mental clarity, and stress adaptability. Following strong results in targeted test markets, NeuroRush™ is scheduled for full commercial release in August/September 2025.
Developed as a premium adaptogen-based formula, NeuroRush™ combines six clinically studied ingredients—including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens—to deliver a balanced, non-jittery experience designed for high-functioning individuals. The product will be available in two formulations: one with natural caffeine for fast-acting mental energy, and a caffeine-free version for users sensitive to stimulants.
“We saw exceptional results in controlled launch markets,” said James Keener, CEO of BioAdaptives. “Customers reported not only better focus and productivity, but also a noticeable improvement in mood, stress control, and cognitive stamina. NeuroRush™ represents our commitment to delivering plant-based performance solutions grounded in science.”
NeuroRush™ is formulated to target multiple pathways involved in brain function and stress resilience, making it ideal for professionals, students, athletes, and older adults seeking enhanced mental performance without dependency or crash. The proprietary blend includes adaptogens, neurotransmitter precursors, and nootropic herbs that work synergistically to support dopamine balance, neuroplasticity, and mental endurance.
BioAdaptives plans to distribute NeuroRush™ through select online retailers, direct-to-consumer channels, and strategic health & wellness partners nationwide. Initial consumer feedback has highlighted NeuroRush™ as a high-performance solution that stands apart from conventional stimulant-based brain products.
About BioAdaptives, Inc.
BioAdaptives, Inc. develops and markets science-based natural health and wellness products for both humans and animals. Its formulations leverage cutting-edge research in stem cell biology, adaptogens, and regenerative nutrition. The company’s mission is to enhance the quality of life through innovation that works in harmony with the body’s natural processes.
For more information, visit: www.bioadaptives.com
Contact:
Emily Harrison
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
When will BioAdaptives (BDPTD) launch NeuroRush™ nationally?
What ingredients are included in BioAdaptives' NeuroRush™ supplement?
How will BioAdaptives distribute NeuroRush™?
What formulations of NeuroRush™ will BDPTD offer?
What benefits did test market users report for BioAdaptives' NeuroRush™?
